미국의 바이러스 백신 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 서비스별, 워크플로우별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

U.S. Viral Vaccines CDMO Market Trends:

The U.S. viral vaccines CDMO market size was estimated at USD 750.2 million in 2024 and is projected to grow at a CAGR of 14.94% from 2025 to 2033. The growth is primarily attributed to strong government funding, advancements in vaccine technologies, and increasing demand for rapid, scalable production. Additionally, CDMOs with advanced capabilities such as single-use systems, lipid nanoparticle formulation, and fill-finish services are in high demand as pharmaceutical companies increasingly outsource to reduce costs and speed up timelines. Strategic partnerships, pandemic preparedness goals, and support from organizations like CEPI further the market growth.

The rising prevalence of viral diseases such as Respiratory Syncytial Virus (RSV), influenza, and monkeypox is accelerating demand for the U.S. viral vaccines CDMO market. Following pandemic-related trends, RSV surged significantly in 2022, resulting in hospitalizations among infants under six months, which increased sevenfold compared to pre-pandemic levels. Meanwhile, influenza test positivity in early 2025 rose to 18.7% across 44 states, along with rising hospitalizations and pediatric fatalities. At the same time, the monkeypox outbreak during 2022-2023 accounted for over 34,700 U.S. cases, prompting the administration of more than 1 million JYNNEOS vaccines. These surges have compelled public health agencies and vaccine developers to enhance manufacturing capacity, leading to contracts, process development, and infrastructure upgrades through CDMOs. This, in turn, supports market growth in the U.S.

The growth of the U.S. viral vaccines CDMO industry is significantly driven by public health emergencies and increasing demand for scalable, rapid vaccine production. Programs like Operation Warp Speed have catalyzed partnerships between the government and CDMOs, with over USD 10 billion in funding allocated to expand domestic manufacturing for COVID-19 and future outbreaks. This focus on pandemic readiness has led to long-term contracts through entities like BARDA, fostering consistent CDMO project pipelines. At the same time, pharmaceutical and biotech firms are increasingly outsourcing vaccine development and manufacturing to CDMOs to reduce upfront capital investments, accelerate time to market, and manage risks across complex viral platforms. Outsourcing also allows companies to concentrate on core R&D activities while leveraging CDMOs' regulatory expertise and GMP infrastructure. This strategic shift, particularly evident in viral-vectored and multivalent vaccine development, positions U.S.-based CDMOs as key enablers of national biosecurity and public-private preparedness, enhancing long-term market growth opportunities.

U.S. Viral Vaccines CDMO Market Report Segmentation

This report forecasts revenue growth country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. viral vaccines CDMO market report based on type, workflow, service, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Attenuated Vaccine
• Inactivated Vaccine
• DNA Vaccines
• Subunit Vaccines
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical
• Commercial
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Formulation & Process Development
  • Upstream Development
  • Downstream Development
• Analytical Testing
• Fill-Finish Services
• Packaging & Labeling
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Companies
• Academic & Research Institutes
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Regulatory Framework
• 3.6. Product Pipeline Analysis
• 3.7. Industry Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL Analysis
  • 3.7.3. COVID-19 Impact Analysis

Chapter 4. U.S. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Viral Vaccines CDMO Market: Type Movement Analysis
• 4.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
• 4.4. Attenuated Vaccine
  • 4.4.1. Attenuated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Inactivated Vaccine
  • 4.5.1. Inactivated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. DNA Vaccines
  • 4.6.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Subunit Vaccines
  • 4.7.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Viral Vaccines CDMO Market; Service Movement Analysis
• 5.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
• 5.4. Formulation & Process Development
  • 5.4.1. Formulation & Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Upstream Development
    • 5.4.2.1. Upstream Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Downstream Development
    • 5.4.3.1. Downstream development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Analytical Testing
  • 5.5.1. Analytical Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Fill-Finish Services
  • 5.6.1. Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Packaging & Labeling
  • 5.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Viral Vaccines CDMO Market; Workflow Movement Analysis
• 6.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
• 6.4. Clinical
  • 6.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Commercial
  • 6.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Viral Vaccines CDMO Market; End Use Movement Analysis
• 7.3. Viral Vaccines CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• 7.4. Biopharmaceutical Companies
  • 7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Academic and Research Institutes
  • 7.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Company Market Assessment Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Lonza
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Catalent, Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Thermo Fisher Scientific, Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Fujifilm Diosynth Biotechnologies
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Samsung Biologics
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Emergent BioSolutions
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Recipharm AB.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Boehringer Ingelheim BioXcellence
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Alcami Corporation
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Vetter Pharma
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives